Ataraxis AI

Ataraxis is an AI precision medicine company revolutionizing cancer diagnosis and patient outcomes through the power of artificial intelligence. Backed by leading investors Giant Ventures and Obvious Ventures, the company is addressing previously unsolved challenges in cancer prognosis and treatment selection using cutting-edge foundational models and multimodal data. Ataraxis’s first clinically validated product, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer, offering higher accuracy than standard-of-care genomic tests.